High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: A pilot study

Digestive Diseases and Sciences

Volumn 49, Issue 7-8, 2004, Pages 1280-1286

  Mow, William S ^a   Landers, Carol J ^a   Steinhart, A Hillary ^b   Feagan, Brian G ^c   Croitoru, Ken ^d   Seidman, Ernest ^e   Greenberg, Gordon R ^b   Targan, Stephan R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

antibiotic therapy; ASCA; budesonide; Crohn's disease; I2; OmpC

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; BUDESONIDE; CIPROFLOXACIN; MARKER; METRONIDAZOLE; OUTER MEMBRANE PROTEIN C;

ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG USE; HUMAN; ILEUM DISEASE; PILOT STUDY; PRIORITY JOURNAL; REMISSION; SEROLOGY;

ANTI-INFECTIVE AGENTS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIGENS, BACTERIAL; BUDESONIDE; CIPROFLOXACIN; CROHN DISEASE; DRUG THERAPY, COMBINATION; HUMANS; METRONIDAZOLE; PILOT PROJECTS; PORINS; PSEUDOMONAS FLUORESCENS; REMISSION INDUCTION; SUPERANTIGENS;

EID: 4444349841     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000037824.66186.e2     Document Type: Article

References (34)

1. Strober W, Fuss IJ, Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol 20:495, 2002
2. De Winter H, Cheroutre H, Kronenberg M: Mucosal immunity and inflammation. II. The yin and yang of T cells in intestinal inflammation: Pathogenic and protective roles in a mouse colitis model. Am J Physiol 276:G1317, 1999
3. Pizarro TT, Arseneau KO, Bamias G, Cominelli F: Mouse models for the study of Crohn's disease. Trends Mol Med 9:218, 2003
4. Shanahan F: The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol 16:915, 2002
5. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F: Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52:975, 2003
6. Cong Y, Brandwein SL, McCabe RP, Lazenby A, Birkenmeier EH, Sundberg JP, Elson CO: CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease. J Exp Med 187:855, 1998
7. Cong Y, Weaver CT, Lazenby A, and Elson CO: Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. J Immunol 169:6112, 2002
8. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB: Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66:5224, 1998
9. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114:262, 1998
10. Gupta P, Andrew H, Kirschner BS, Guandalini S: Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 31:453, 2000
11. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45:1462, 2000
12. Dunne C, O'Mahony L, Murphy L, Thornton G, Morrissey D, O'Halloran S, Feeney M, Flynn S, Fitzgerald G, Daly C, Kiely B, O'Sullivan GC, Shanahan F, Collins JK: In vitro selection criteria for probiotic bacteria of human origin: Correlation with in vivo findings. Am J Clin Nutr 73:386S, 2001
13. Shanahan F: Turbo probiotics for IBD. Gastroenterology 120:1297, 2001
14. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Targan SR, Braun J: Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 68:1542, 2000
15. Eggena M, Cohavy O, Parseghian MH, Hamkalo BA, Clemens D, Targan SR, Gordon LK, Braun J: Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. Autoimmun 14:83, 2000
16. Quintan JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D: Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut 42:788, 1998
17. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C: An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 91:328, 1996
18. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C: Antimycobacterial therapy in Crohn's disease: Results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 89:513, 1994
19. Prantera C, Kohn A, Zannoni F, Spimpolo N, Bonfa M: Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: Results of an open study. J Clin Gastroenterol 19:79, 1994
20. Greenbloom SL, Steinhart AH, Greenberg GR: Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 12:53, 1998
21. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR: Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial. Gastroenterology 123:33, 2002
22. Hugor JP, Chamailard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Aimer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G: Association of NOD2 leucine-rich repeat vaiants with susceptibility to Crohn's disease. Nature 411:599, 2001
23. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nunez G: Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278:5509, 2003
24. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603, 2001
25. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 96:730, 2001
26. Satsangi J, Landers CJ, Welsh KI, Koss K, Targan S, Jewell DP: The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis 4:18, 1998
27. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG: Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 115:822, 1998
28. Tanabe T, Chamaillard M, Ogura Y, Zhu L, Qiu S, Masumoto J, Ghosh P, Moran A, Predergast MM, Tromp G, Williams CJ, Inohara N, Nunez G: 2004. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J 23:1587, 2004
29. Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, Targan SR, Braun J: Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 119:23, 2000
30. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR: Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 123:689, 2002
31. Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J: Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 46:58, 2000
32. Saxon A, Shanahan F, Landers C, Ganz T, Targan S: A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 86:202, 1990
33. Sutherland L, Singleton J, Sessions J, et al.: Double blind placebo controlled trial of metronidazole in Crohn's disease. Gut 32:1071, 1991
34. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR: ANCA pattern and LTA haplotype relatioship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 120:1347, 2001